Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Revenue (2016 - 2021)

Corbus Pharmaceuticals Holdings has reported Revenue over the past 7 years, most recently at $97323.0 for Q3 2021.

  • For Q3 2021, Revenue fell 92.09% year-over-year to $97323.0; the TTM value through Jun 2022 reached $97323.0, down 97.39%, while the annual FY2021 figure was $881705.0, 82.37% down from the prior year.
  • Revenue for Q3 2021 was $97323.0 at Corbus Pharmaceuticals Holdings, down from $136558.0 in the prior quarter.
  • Over five years, Revenue peaked at $29.1 million in Q2 2019 and troughed at -$28.6 million in Q4 2019.
  • A 5-year average of $912103.7 and a median of $902044.0 in 2018 define the central range for Revenue.
  • On a YoY basis, Revenue climbed as much as 3308.27% in 2019 and fell as far as 14313.95% in 2019.
  • Year by year, Revenue stood at $796312.0 in 2017, then plummeted by 74.76% to $201000.0 in 2018, then plummeted by 14313.95% to -$28.6 million in 2019, then soared by 106.02% to $1.7 million in 2020, then crashed by 94.34% to $97323.0 in 2021.
  • Business Quant data shows Revenue for CRBP at $97323.0 in Q3 2021, $136558.0 in Q2 2021, and $647824.0 in Q1 2021.